A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
for Advanced Solid Tumor
23 locations incl. Tucson
Sponsor: Eikon Therapeutics
Sex: All·Age: 18 - 89
Code: NCT06253130·Phase 1, Phase 2·Recruiting